## Quarterly Community Provider Network (CPN) Meeting

**Time:** 7:30 AM – 9:00 AM  
**Date:** October 15, 2019  
**Location:** West County Health Center  
13601 San Pablo Ave, Room A, San Pablo, CA.  
*Attention! Please enter through the side door (on San Pablo Ave.)*

<table>
<thead>
<tr>
<th>I. CALL TO ORDER and INTRODUCTIONS</th>
<th>Christine Gordon, RN, BSN, PHN, DHCS-MT</th>
</tr>
</thead>
<tbody>
<tr>
<td>II. REVIEW and APPROVAL of Previous Meeting Minutes</td>
<td>Christine Gordon, RN, BSN, PHN, DHCS-MT</td>
</tr>
<tr>
<td>III. IHA, SHA, USPSTF</td>
<td>Christine Gordon, RN, BSN, PHN, DHCS-MT</td>
</tr>
<tr>
<td>• IHA, SHA, USPSTF</td>
<td>2019 DHCS: New FSR/MRR Tools</td>
</tr>
</tbody>
</table>
| IV. GUEST SPEAKERS | Belkys Teutle, Member Services Manager  
Michelle Rivero/Jody Adelberg  
Pediatric Public Health |
| • Member Grievance Process |  
• Fluoride Varnish |
| V. REGULAR REPORTS | Jose Yasul, MD  
Medical Director, CCHP |
| 1. Legislative / CCHP Update |  
• California Advancing and Innovating Medi-Cal (Cal-AIM)  
• DMHC/DHCS Audit highlights |
| 2. CCHP Benefits update |  
• NEMT Transportation form DMHC/DHCS Audit highlights  
• Updates to “No Auth” list |
| 3. Quality |  
• NCQA – “Commendable” rating  
• Population Heath Performance Improvement Projects (PIP’s) |
| 4. Pharmacy |  
• Review Care Matters |
| 5. Utilization Management |  
• Q and A |
| VI. CLAIMS Q&A | Claims Unit Staff |

Our next scheduled meeting is January 21, 2020  
CPN meeting reimbursement will be prorated based on length of time attendee is present in the meeting.
CONTRA COSTA HEALTH PLAN  
West County  
Quarterly Community Provider Network (CPN)  
Meeting Minutes – October 15, 2019

Attending:
CCHP Staff: Jose Yasul, MD, Medical Director; Christine Gordon, RN, BSN, DHCS-MT; Jonel Sangalang, Clerical Support; Sylvia Rodriguez, Claims Supervisor
CPN Providers: J. An, MD; K. Ceci, MD; A. Girard, FNP; K. Merchant, MD; M. Ogawa, MD; P. Rene, PA; J. Ritterman, MD; N. Stern, MD; L. Trombla, PA; A. Wallach, MD
Guest Michelle Rivero; Jody Adelberg, RN, PHN, MSN; S'Deja Alfred

<table>
<thead>
<tr>
<th>Discussion</th>
<th>Action</th>
<th>Accountable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meeting called to order at 7:46 A.M.</td>
<td></td>
<td>Christine Gordon, RN, BSN, DHCS-MT</td>
</tr>
<tr>
<td>I.</td>
<td>Minutes were approved with no revisions.</td>
<td>Jose Yasul, MD Medical Director, CCHP</td>
</tr>
<tr>
<td>II. Reminders</td>
<td></td>
<td>Christine Gordon, RN, BSN, DHCS-MT</td>
</tr>
<tr>
<td>• Initial Health Assessment (IHA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o Must be completed within 120 days of enrollment into the health plan or documented within the 12 months prior to Plan enrollment.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o If member assigned to new PCP, IHA must be completed within 120 days of that assignment if no IHA documented within the past 12 months.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o IHA includes H&amp;P, IHEBA (SHA), USPSTF screenings, ensure up-to-date immunizations per ACIP.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o Perinatal depression screening.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o Gonococcal Ophthalmic Neonatorum screening.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• USPSTF Update:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o Colorectal cancer screening</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o Lipid screening – children only</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o Post-partum depression screening for new moms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o Intimate partner violence screening</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o Folic acid supplementation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o Immunization registry reporting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Facility, site and medical record review tools from DHCS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o Extensive review</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o Spend more time at the facilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o USPSTF screenings</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o PowerPoint will be sent to the PCPs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III. Guest Speaker</td>
<td></td>
<td>Jody Adelberg, CHDP Pediatric Nurse Practitioner</td>
</tr>
<tr>
<td>Dental Varnish</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• CHDP Care coordination</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o Fee For Service Medi-Cal kids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o Children in foster care</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
• Fluoride Varnish application training
• Apply fluoride varnish at the well child visit
• Application up to two to four times a year or every six months
• Brushing of protective resin coating of the sodium fluoride that goes on the teeth
• Reimbursable by Medi-Cal
• Helps to support a healthy dental remineralization
• Prevent and inhibit bacterial growth
• Baby teeth affect the permanent teeth
• Educate parents
• Baby bottle tooth decay – prolong carbohydrate exposure
• Swish, rinse and spit out
• Can be done in the dental office

IV Regular Reports - CCHP Updates

• NCQA – Commendable rating
• California Advancing and Innovating Medi-Cal (Cal-AIM)
  o Waiver program
• Respite care
  o Secure housing
• Behavioral health (Mid to moderate)
  o Integrated health plan system
• Medi-Cal carve out all drugs plan
• Non-Emergency Transportation form – Gurney
• Non-Medical Transportation form – Social visit
• Provider orientation packet
• Provider Manual
  o “No Auth” list
    ▪ 3,000 to 9,000 on list
  o Omron 3 blood pressure cuff
    ▪ Send prescription to pharmacy
  o Pharmacy and Therapeutics update
    ▪ HPV vaccine – MMR update
    ▪ Steroids – injection on No Auth list
    ▪ Apidra to Lispro
    ▪ Roxy condone back on formulary
    ▪ Apidra to Lispro
    ▪ Roxicodone back on formulary
• Lactation program
• Concussion protocol with Stat Med

Adjournment:
Meeting adjourned at 9:00 A.M.

Next meeting January 21, 2020
Dental caries remains the most common chronic disease of childhood in the United States. Caries is a largely preventable condition, and fluoride has proven effectiveness in the prevention of caries. The goals of this clinical report are to clarify the use of available fluoride modalities for caries prevention in the primary care setting and to assist pediatricians in using fluoride to achieve maximum protection against dental caries while minimizing the likelihood of enamel fluorosis. 

Dental caries (ie, tooth decay) is an infectious disease in which acid produced by bacteria dissolves tooth enamel. If not halted, this process will continue through the tooth and into the pulp, resulting in pain and tooth loss. This activity can further progress to local infections (ie, dental alveolar abscess or facial cellulitis), systemic infection, and, in rare cases, death. Dental caries in the United States is responsible for many of the 51 million school hours lost per year as a result of dental-related illness, which translates into lost work hours for the parent or adult caregiver. Early childhood caries is the single greatest risk factor for caries in the permanent dentition. Good oral health is a necessary part of overall health, and recent studies have demonstrated the adverse effects of poor oral health on multiple other chronic conditions, including diabetes control. Therefore, the failure to prevent caries has health, educational, and financial consequences at both the individual and societal level.

Dental caries is the most common chronic disease of childhood, with 50% of 12- to 19-year-olds having at least 1 documented cavity. Caries is the “silent epidemic” that disproportionately affects poor, young, and minority populations. The prevalence of dental caries in very young children increased during the period between the last 2 national surveys, despite improvements for older children. Because many children do not receive dental care at young ages, and risk factors for dental caries are influenced by parenting practices, pediatricians have a unique opportunity to participate in the primary prevention of dental caries. Studies show that simple home and primary care setting prevention measures would save health care dollars.

Development of dental caries requires 4 components: teeth, bacteria, carbohydrate exposure, and time. Once teeth emerge, they may become colonized with cariogenic bacteria. The bacteria metabolize carbohydrates...
reversed by modifying the patient
to colonization. If carious lesions are iden-
tified early, the process can be halted or reversed by modifying the patient’s individual risk and protective factors. Certain American Academy of Pediatrics (AAP) publications (Oral Health Risk Assessment Timing and Establishment of the Dental Home6 and Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents9) discuss these concepts in greater depth and provide targeted preventive anticipatory guidance. The Medical Expenditure Panel Survey demonstrated that 89% of infants and 1-year-olds have office-based physician visits annually, compared with only 1.5% who have dental visits.10 For primary prevention to be effective, it is imperative that pediatricians be knowledgeable about the process of dental caries, prevention of the disease, and available interventions, including fluoride.

Fluoride is available from many sources and is divided into 3 major categories: tap water (and foods and beverages processed with fluoridated water), home administered, and professionally applied. There has been substantial public and professional debate about fluoride, and myriad information is available, often with confusing or conflicting messages. The widespread decline in dental caries in many developed countries, including the United States, has been largely attributable to the use of fluoride. Fluoride has 3 main mechanisms of action: (1) it promotes enamel remineralization; (2) it reduces enamel demineralization; and (3) it inhibits bacterial metabolism and acid production.8 The mechanisms of fluoride are both topical and systemic, but the topical effect is the most important, especially over the life span.10

**RISK OF FLUOROSIS**

The only scientifically proven risk of fluoride use is the development of fluorosis, which may occur with fluoride ingestion during tooth and bone development. Fluorosis of permanent teeth occurs when fluoride of sufficient quantity for a sufficient period of time is ingested during the time that tooth enamel is being mineralized. Fluorosis is the result of subsurface hypomineralization and porosity between the developing enamel rods.11 This risk exists in children younger than 8 years, and the most susceptible period for permanent maxillary incisor fluorosis is between 15 and 30 months of age.12–14 The risk of fluorosis is influenced by both the dose and frequency of exposure to fluoride during tooth development.15 Recent evidence also suggests that individual susceptibility or resistance to fluorosis includes a genetic component.16

After 8 years of age, there is no further risk of fluorosis (except for the third molars) because the permanent tooth enamel is fully mineralized. The vast majority of enamel fluorosis is mild or very mild and characterized by small white striations or opaque areas that are not readily noticeable to the casual observer. Although this type of fluorosis is of no clinical consequence, enamel fluorosis has been increasing in frequency over the last 2 decades to a rate of approximately 41% among adolescents because fluoride sources are more widely available in varied forms.17 Moderate and severe forms of enamel fluorosis are uncommon in the United States but have both an aesthetic concern and potentially a structural concern, with pitting, brittle incisal edges, and weakened groove anatomy in the permanent 6-year molars.

In 2001, the AAP endorsed the guidelines from the Centers for Disease Control and Prevention (CDC), “Recommendations for Using Fluoride to Prevent and Control Dental Caries in the United States.”15 Dental and governmental organizations (American Dental Association [ADA], American Academy of Pediatric Dentistry, the Department of Health and Human Services, and the CDC) have more recently published guidelines on the use of fluoride, but current AAP publications do not reflect these newer evidence-based guidelines. Table 1 provides a simple explanation of fluoride use for patients at low and high risk of caries.

The present report has 2 goals: (1) to assist pediatricians in using fluoride to achieve maximum protection against

<table>
<thead>
<tr>
<th>Fluoride Modality</th>
<th>Low Caries Risk</th>
<th>High Caries Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toothpaste</td>
<td>Starting at tooth emergence (smear of paste until age 3 y, then pea-sized)</td>
<td>Starting at tooth emergence (smear of paste until age 3 y, then pea-sized)</td>
</tr>
<tr>
<td>Fluoride varnish</td>
<td>Every 3–6 mo starting at tooth emergence</td>
<td>Every 3–6 mo starting at tooth emergence</td>
</tr>
<tr>
<td>Over-the-counter mouth rinse</td>
<td>Not applicable</td>
<td>Starting at age 6 y if the child can reliably swish and spit</td>
</tr>
<tr>
<td>Community water fluoridation</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Dietary fluoride supplements</td>
<td>Yes, if drinking water supply is not fluoridated</td>
<td>Yes, if drinking water supply is not fluoridated</td>
</tr>
</tbody>
</table>
dental caries while minimizing the likelihood of enamel fluorosis; and (2) to clarify the advice that should be given by pediatricians regarding fluoride in the primary care setting.

CURRENT INFORMATION REGARDING FLUORIDE USE IN CARIES PREVENTION

The following information aims to assist pediatricians in achieving maximum protection against dental caries for their patients while minimizing the likelihood of enamel fluorosis. Sources of ingested fluoride include drinking water, infant formula, fluoride toothpaste, prescription fluoride supplements, fluoride mouth rinses, professionally applied topical fluoride, and some foods and beverages.18

Fluoride Toothpaste

Fluoride toothpaste has consistently been proven to provide a caries-preventive effect for individuals of all ages.15,19 In the United States, the fluoride concentration of over-the-counter toothpaste ranges from 1000 to 1100 ppm. In some other countries, toothpastes containing 1500 ppm of fluoride are available. A 1-inch (1-g) strip of toothpaste translates to 1 or 1.5 mg of fluoride, respectively. A pea-sized amount of toothpaste is approximately one-quarter of an inch. Therefore, a pea-sized amount of toothpaste containing 1000/1100 ppm of fluoride would have approximately 0.25 mg of fluoride, and the same amount of toothpaste containing 1500 ppm of fluoride would have approximately 0.38 mg of fluoride. Most fluoride toothpaste in the United States contains sodium fluoride, sodium monofluorophosphate, or stannous fluoride as the active ingredient. Parents should supervise children younger than 8 years to ensure the proper amount of toothpaste is used and by storing toothpaste where young children cannot access it without parental help.

Use of fluoride toothpaste should begin with the eruption of the first tooth. When fluoride toothpaste is used for children younger than 3 years, it is recommended that the amount be limited to a smear or grain of rice size (about one-half of a pea). Once the child has turned 3 years of age, a pea-sized amount of toothpaste should be used.20,21 Young children should not be given water to rinse after brushing because their instinct is to swallow. Expectorating without rinsing will both reduce the amount of fluoride swallowed and leave some fluoride in the saliva, where it is available for uptake by the dental plaque. Parents should be strongly advised to supervise their child's use of fluoride toothpaste to avoid overuse or ingestion.

High-concentration toothpaste (5000 ppm) is available by prescription only. The active ingredient in this toothpaste is sodium fluoride. This agent can be recommended for children 6 years and older and adolescents who are at high risk of caries and who are able to expectorate after brushing. Dentists may also prescribe this agent for adolescents who are undergoing orthodontic treatment, as they are at increased risk of caries during this time.22

Fluoride Varnish

Fluoride varnish is a concentrated topical fluoride that is applied to the teeth by using a small brush and sets on contact with saliva. Advantages of this modality are that it is well tolerated by infants and young children, has a prolonged therapeutic effect, and can be applied by both dental and non-dental health professionals in a variety of settings.23 The concentration of fluoride varnish is 22 600 ppm (2.26%), and the active ingredient is sodium fluoride. The unit dose packaging from most manufacturers provides a specific measured amount (0.25 mg, providing 5 mg of fluoride ion). The application of fluoride varnish during an oral screening is of benefit to children, especially those who may have limited access to dental care. Current American Academy of Pediatric Dentistry recommendations for children at high risk of caries is that fluoride varnish be applied to their teeth every 3 to 6 months.24 The 2013 ADA guideline recommends application of fluoride varnish at least every 6 months to both primary and permanent teeth in those subjects at elevated caries risk.25 The US Preventive Services Task Force recently published a new recommendation that primary care clinicians apply fluoride varnish to the primary teeth of all infants and children starting at the age of primary tooth eruption (B recommendation).26

In most states, Medicaid will pay physicians for the application of fluoride varnish. Information regarding fluoride varnish application reimbursement and which states currently provide payment can be found on the AAP Web site (http://www2.aap.org/oralhealth/docs/OHReimbursementChart.pdf) and the Pew Charitable Trusts Web site (http://www.pewstates.org/research/analysis/reimbursing-physicians-for-fluoride-varnish-85898377335). Because state regulations vary regarding whether fluoride varnish must be applied within the context of a preventive care code, this information should be determined before billing.

Indications for Use

In the primary care setting, fluoride varnish should be applied to the teeth of all infants and children at least once every 6 months and preferably every 3 months, starting when the first tooth...
erupts and until establishment of a dental home.

**Instructions for Use**

Fluoride varnish must be applied by a dentist, dental auxiliary professional, physician, nurse, or other health care professional, depending on the practice regulations in each state. It should not be dispensed to families to apply at home. Application of fluoride varnish is most commonly performed at the time of a well-child visit. Teeth are dried with a 2-inch gauze square, and the varnish is then painted onto all surfaces of the teeth with a brush provided with the varnish. Children are instructed to eat soft foods and not to brush their teeth on the evening after the varnish application to maximize the contact time of the varnish to the tooth. The following day, they should resume brushing twice daily with fluoridated toothpaste.

**Over-the-Counter Fluoride Rinse**

Over-the-counter fluoride rinse provides a lower concentration of sodium fluoride than toothpaste or varnish. The concentration is most commonly 230 ppm (0.05% sodium fluoride). Expert panels on this topic have concluded that over-the-counter fluoride rinses should not be recommended for children younger than 6 years because of their limited ability to rinse and spit and the risk of swallowing higher-than-recommended levels of fluoride.27 A teaspoon (5 mL) of over-the-counter fluoride rinse contains approximately 1 mg of fluoride. For children younger than 6 years, this type of rinse provides an additional, low-dose topical fluoride application that may assist in the prevention of enamel demineralization. However, the evidence for an anticaries effect is limited. The daily use of a 0.05% sodium fluoride rinse may be of benefit for children older than 6 years who are at high risk of dental caries; however, there is no additional benefit beyond daily use of fluoridated toothpaste for children at low risk of caries.28,29

**Dietary Fluoride Supplements**

Dietary fluoride supplements should be considered for children living in communities in which the community water is not fluoridated or who drink well water that does not contain fluoride.26 Because there are many sources of fluoride in the water supply and in processed food, it is essential that all potential sources of fluoride be assessed before prescribing a dietary supplement, including consideration of differing environmental exposures (eg, dual homes, child care). As a general guideline, if the primary source of water is fluoridated tap or well water, the child will not require fluoride supplementation, even if he or she primarily drinks bottled water; because the teeth are exposed to fluoride through cooking and brushing. The risk of fluorosis is high if fluoride supplements are given to a child consuming fluoridated water.30 Information about the fluoridation levels in many community water systems can be found on the CDC Web site entitled My Water’s Fluoride (http://apps.nccd.cdc.gov/MWF/Index.asp). Not all communities report this information to the CDC; therefore, it may be necessary to contact the local water department to determine the level of fluoride in the community water. Well water must be tested for fluoride content before prescribing supplements; such testing is available in most states through the state or county public health laboratory.

**Guidelines for Use**

CDC recommendations regarding fluoride supplementation are provided in Table 2. Supplements can be prescribed in liquid or tablet form. Tablets are preferable for children old enough to chew, because they gain an additional topical benefit to the teeth during the chewing process. Liquid supplements are recommended for younger children and should ideally be added to water or put directly into the child’s mouth. Addition of the fluoride supplement to milk or formula is not recommended because of the reduced absorption of fluoride in the presence of calcium.51 The risk of mild fluorosis can be minimized by health care providers verifying that there are no other sources of fluoride exposure before prescribing systemic fluoride supplements.

**Other Sources of Fluoride**

Fluoride is present in processed foods and beverages and may be naturally occurring in some areas of the country. The presence of fluoride in juices and carbonated beverages does not counteract the cariogenic nature of these beverages.

**Reconstitution of Infant Formula**

In a study of infant feeding practices, 70% to 75% of mothers who fed their infants formula used tap water to reconstitute the powdered formula.32 According to CDC data from 2012, approximately 67% of US households using public water supplies received

---

**TABLE 2 Fluoride Supplementation Schedule for Children**

<table>
<thead>
<tr>
<th>Age</th>
<th>Fluoride Ion Level in Drinking Watera</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;0.3 ppm</td>
</tr>
<tr>
<td>Birth–6 mo</td>
<td>None</td>
</tr>
<tr>
<td>6 mo–3 y</td>
<td>0.25 mg/d</td>
</tr>
<tr>
<td>3–6 y</td>
<td>0.50 mg/d</td>
</tr>
<tr>
<td>6–16 y</td>
<td>1.0 mg/d</td>
</tr>
</tbody>
</table>

Source: Centers for Disease Control and Prevention.46

a 1 ppm = 1 mg/L.
b 2.2 mg of sodium fluoride contains 1 mg of fluoride ion.

---
optimal fluoride levels (between 0.7 and 1.2 ppm).^{35}

**ADA Evidenced-Based Clinical Recommendations**

In 2011, the ADA Council on Scientific Affairs examined the existing evidence and made 2 recommendations. The first recommendation supported the continued use of optimally fluoridated water to reconstitute powdered and liquid infant formula, being cognizant of the small risk of fluorosis in permanent teeth. The second recommendation stated that if there was concern about the risk of mild fluorosis, the formula could be reconstituted with bottled (nonfluoridated) water.^{18} It should be noted that most bottled water has suboptimal levels of fluoride and that fluoride content is not listed unless it is added.

**Community Water Fluoridation**

Community water fluoridation is the practice of adding a small amount of fluoride to the water supply. It has been heralded as 1 of the top 10 public health achievements of the 20th century by the CDC.^{34} Community water fluoridation is a safe, efficient, and cost-effective way to prevent tooth decay and has been shown to reduce tooth decay by 29%.^{35} It prevents tooth decay through the provision of low levels of fluoride exposure to the teeth over time and provides both topical and systemic exposure. It is estimated that every dollar invested in water fluoridation saves $38 in dental treatment costs (http://www.cdc.gov/fluoridation/benefits/). Currently, although more than 210 million Americans live in communities with optimally fluoridated water, there are more than 70 million others with public water systems who do not have access to fluoridated water.^{35} The fluoridation status of a community water supply can be determined by contacting the local water department or accessing the Web site My Water’s Fluoride (http://apps.nccd.cdc.gov/MWF/Index.asp).

**Recommended Concentration**

Water fluoridation was initiated in the United States in the 1940s. In January 2011, the US Department of Health and Human Services proposed a change to lower the optimal fluoride level in drinking water. The proposed new recommendation is 0.7 mg of fluoride per liter of water to replace the previous recommendation, which was based on climate and ranged from 0.7 mg/L in the warmest climates to 1.2 mg/L in the coldest climates.^{56} The change was recommended because recent studies showed no variation in water consumption by young children based on climate and to adjust for an overall increase in sources of fluoride (foods and beverages processed with fluoridated water and fluoridated mouth rinses and toothpastes) in the American diet.

**Evidence Supporting Community Water Fluoridation**

Despite overwhelming evidence supporting the safety and preventive benefits of fluoridated water, community water fluoridation continues to be a controversial and highly emotional issue. Opponents express a number of concerns, all of which have been addressed or disproven by validated research. The only scientifically documented adverse effect of excess (nontoxic) exposure to fluoride is fluorosis. An increase in the incidence of mild enamel fluorosis among teenagers has been cited as a reason to discontinue fluoridation, even though this condition is cosmetic with no detrimental health outcomes. Recent opposition has sometimes centered on the question of who decides whether to fluoridate (elected/public officials or the voters), possibly reflecting a recent trend of distrust of the US government. Many opponents believe fluoridation to be mass medication and call the ethics of community water fluoridation into question, but courts have consistently held that it is legal and appropriate for a community to adopt a fluoridation program.^{57} Opponents also express concern about the quality and source of fluoride, claiming that the additives (fluorosilicic acid, sodium fluoride, or sodium fluorosilicate), in their concentrated form, are highly toxic and are byproducts of the production of phosphate fertilizer and may include other contaminants, such as arsenic. The quality and safety of fluoride additives are ensured by Standard 60 of the National Sanitation Foundation/American National Standards Institute, a program commissioned by the Environmental Protection Agency (EPA), and testing has been conducted to confirm that arsenic or other substances are below the levels allowed by the EPA.^{58} Finally, there have been many unsubstantiated or discredited claims that fluoride leads to kidney disease, bone cancer, and compromised IQ. More than 3000 studies or research papers have been published on the subject of fluoride or fluoridation.^{59} Few topics have been as thoroughly re-searched, and the overwhelming weight of the evidence—in addition to 68 years of experience—supports the safety and effectiveness of this public health practice.

**Naturally Occurring Fluoride in Drinking Water**

The optimal fluoride level in drinking water is 0.7 to 1.2 ppm, an amount that has been proven beneficial in reducing tooth decay. Naturally occurring fluoride may be below or above these levels in some areas. Under the Safe Drinking Water Act (Pub L No. 93-523 [1974]), the EPA requires notification by the water supplier if the fluoride level exceeds 2 ppm. In areas where naturally occurring fluoride levels in drinking water exceed 2 ppm, people should consider an alternative water source or home water treatments to reduce the risk of
fluorosis in young children.40 Well water should be tested for the level of fluoride; this testing is most commonly performed through the health department.

Fluoride Toxicity

Toxic levels of fluoride are possible, particularly in children, as a result of ingesting large quantities of fluoride supplements. The toxic dose of elemental fluoride is 5 to 10 mg of fluoride per kilogram of body weight.41 Lethal doses in children have been calculated to be between 8 and 16 mg/kg. When prescribing sodium fluoride supplements, it is recommended to limit the quantity prescribed at one time to no more than a 4-month supply. Parents should be advised to keep fluoride products out of the reach of young children and to supervise their use.

Fluoride Removal Systems

There are a number of water treatment systems that are effective in the removal of fluoride from water,42 including reverse osmosis and distillation. Parents should be counseled on the use of these and activated alumina filters in the home and, should they choose to use one that removes fluoride, the potential effect on their family’s oral health. Commonly used home carbon filters (eg, Brita [Brita LP, Oakland, California], PUR [Kaz USA, Incorporated, Southborough, MA]) do not remove fluoride. These can be recommended for families who are concerned about heavy metals or other impurities in their home water supply but who wish to retain the benefits of fluoridated water.

SUGGESTIONS FOR PEDIATRICIANS

1. Know how to assess caries risk. As recommended by the AAP’s Oral Health Risk Assessment Timing and Establishment of the Dental Home and Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, pediatricians should perform oral health risk assessments on all children at preventive visits beginning at 6 months of age. An oral health risk assessment tool has been developed by the AAP/Bright Futures and endorsed by the National Interprofessional Initiative on Oral Health. This tool can be accessed at http://www2.aap.org/oralhealth/RiskAssessment-Tool.html. There are currently no validated early childhood caries risk assessment tools. The aforementioned tool is a guide to help clinicians counsel patients about oral health and best identify risk.

2. Know how to assess a child’s exposure to fluoride and determine the need for topical or systemic supplements.43

3. Understand indications for fluoride varnish and how to provide it. Fluoride varnish can be a useful tool in the prevention of early childhood caries. Additional training on oral screenings, fluoride varnish indications and application, and office implementation can be found in the Smiles for Life Curriculum Course 6: Caries Risk Assessment, Fluoride Varnish and Counseling44 at www.smilesforlifeoralhealth.org. In addition, the AAP Children’s Oral Health Web site is a resource for oral health practice tools (http://www2.aap.org/oralhealth/PracticeTools.html).

4. Advocate for water fluoridation in the local community. Public water fluoridation is an effective and safe method of protecting the most vulnerable members of our population from dental caries. Pediatricians are encouraged to advocate on behalf of public water fluoridation in their communities and states. For additional information and water fluoridation facts and detailed questions and answers, see http://www.ada.org/sections/newsAndEvents/pdfs/fluoridation_facts.pdf, http://www.cdc.gov/fluoridation/, and http://www.ilikemyteeth.org.

REFERENCES


LEAD AUTHORS

Melinda B. Clark, MD, FAAP
Rebecca L. Slayton, DDS, PhD

SECTION ON ORAL HEALTH EXECUTIVE COMMITTEE, 2011–2012

Adriana Segura, DDS, MS, Chairperson
Suzanne Boulter, MD, FAAP
Melinda B. Clark, MD, FAAP
Rani Gereige, MD, FAAP
David Krol, MD, MPH, FAAP
Wendy Mouradian, MD, FAAP
Rocio Quinonez, DMD, MPH
Francisco Ramos-Gomez, DDS
Rebecca L. Slayton, DDS, PhD
Martha Ann Keels, DDS, PhD, Immediate Past Chairperson

LIAISONS

Joseph Castellano, DDS – American Academy of Pediatric Dentistry
Sheila Strock, DMD, MPH – American Dental Association Liaison

STAFF

Lauren Barone, MPH


Fluoride Use in Caries Prevention in the Primary Care Setting
Melinda B. Clark, Rebecca L. Slayton and SECTION ON ORAL HEALTH

*Pediatrics* 2014;134;626
DOI: 10.1542/peds.2014-1699 originally published online August 25, 2014;

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://pediatrics.aappublications.org/content/134/3/626
May 2019

Dear CHDP Providers,

The Contra Costa County Child Health Disability Prevention (CHDP) Program, is now recommending fluoride varnish to all children ages six months (or after the eruption of the first tooth) thru five years old. This is in order to maintain and improve the oral health of young children in primary settings and also for the prevention of caries, as per the American Academy of Pediatrics (AAP), Recommendations for Preventive Pediatric Health Care Periodicity Schedule, regarding children’s oral health, since 2015. (See www.aap.org/periodicitieschedule).

Fluoride varnishing that is now recommended 2-4 times annually, or every 3-6 months, has been shown to decrease and prevent oral caries, by supporting healthy tooth enamel while preventing bacterial damage to dentition. See article “Fluoride Use in Caries Prevention in the Primary Care Setting,” (http://pediatrics.aappublications.org/content/134/3/626). If parents have concerns regarding the benefits vs risks of fluoride varnish usage, please refer them to their primary care providers.

This procedure of brush varnishing, the dentition with a protective resin coating with sodium fluoride, can be done in the primary care provider’s office setting. It also can be done in the dentist’s office, that has been established after a child’s first birthday. Medi-Cal will pay physicians for the application of fluoride varnish. See pages 20-21 of the December 2018, “California CHDP/EPSDT Dental Training: Fluoride Varnish” manual, regarding Medi-Cal billing, CPT codes and purchasing fluoride varnish kits for office usage. (http://www.dhcs.ca.gov/services/chdp/Pages/FluorideVarnish.aspx) Also, the complete fluoride varnish training is provided in the “California CHDP/EPSDT Dental Training: Fluoride Varnish,” manual, as referenced above.

Please review this training manual.

Contra Costa County CHDP staff, will be providing additional training for your office staff, as needed. We will contact you in the coming weeks, with further information regarding these trainings.

Thank you,

Michelle Rivero
Child Health and Disability Prevention Program
2500 Bates Ave., Suite B
Concord, CA 94520
925-313-6150
chdp@cchealth.org
California CHDP/EPSDT Dental Training: Fluoride Varnish

Child Health and Disability Prevention (CHDP) Program Oral Health Subcommittee December 2018

CHDP Dental Training: Fluoride Varnish Materials
http://www.dhcs.ca.gov/services/chdp/Pages/FluorideVarnish.aspx
Training Objectives

• Identify children at risk for dental decay and who would benefit from fluoride varnish.
• Recognize the importance of providing fluoride varnish to high risk children (0 up to 6 years) in the medical office.
• Establish a protocol to implement fluoride varnish application in the medical office.
• Apply fluoride varnish and share information with other office staff.
Fluoride Varnish

The CHDP/EPSDT Medical Provider Role
CHDP Providers Prevent Dental Decay

- Young children are seen earlier and more frequently by medical providers than by a dentist
- Low income young children are often at higher risk for dental decay
- Medical providers are now placing fluoride varnish to prevent decay
- Research shows high efficacy of fluoride varnish*

*Fluoride Varnish Efficacy in Preventing Early Childhood Caries
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2257982/?tool=pubmed
In 2017, Indiana was the final state to provide compensation through Medicaid to pediatric health professionals for fluoride varnish services.

2011

Reimbursing Physicians for Fluoride Varnish
Fluoride Varnish – Who Needs It?

Caries Risk Factors:

• **Low Socioeconomic Status (SES)**

• **Active or Past Tooth Decay**
  – In parents, siblings, caregivers or child
  – White spot lesions on teeth

• **Poor Feeding Habits**
  – Frequent sipping and snacking on:
    • Carbohydrates – not just refined sugars
  – Bottle while sleeping/napping
  – Bottle after age 1

Oral Health Risk Assessment Tool (AAP)
https://brightfutures.aap.org/Bright%20Futures%20Documents/Oral%20Health%20Risk%20Assessment%20Tool.pdf
Fluoride Varnish – Who Needs It?

Caries Risk Factors (continued):

• **Lack of Fluoride Exposure***
• **No Recent Dental Visit**
  – Within the last year
• **Poor Homecare**
  – Lack of daily brushing and flossing
• **Children with Special Health Care Needs**

*California Water Board: List of Fully Fluoridated Water Systems (Fluoridation by Public Water)
https://www.waterboards.ca.gov/drinking_water/certlic/drinkingwater/Fluoridation.html
Fluoride Varnish – Which Teeth Benefit?

No Visible Decay
but may have high risk factors

Preventable with fluoride varnish and good home care

Beginning Decay
white chalky decalcification near gum line

Reversible with fluoride varnish and improved home care to inhibit progression of caries

Advanced Decay
Destroyed enamel

Irreversible, however with fluoride varnish decay progression is inhibited

Dental treatment needed ASAP

DO NOT Apply to Teeth with
pulp exposure or tissue lesions

Avoid these areas, but apply fluoride varnish to all other teeth in the mouth.
Immediate treatment needed for severe decay
Fluoride Varnish - Facts

• A protective resin coating with sodium fluoride
• Brushed on teeth in 1-2 minutes
• 1 application can reduce decay risk up to 59%*
• Applied up to 5x per year
  – 3x in medical office
  – 2x in dental office
Frequency of Application

• Apply during a well child exam, follow-up visit, or stand-alone appointment.

• After the first fluoride varnish treatment, subsequent treatments can be applied every 3-4 months.
Fluoride Varnish Safety

• Fluoride varnish is recommended even if other types of fluoride are being used, including:
  – Systemic fluoride (e.g. water fluoridation, tablets or drops)
  – Other topical fluorides (e.g. fluoridated toothpaste, mouth rinses, foam or gel trays)

• Contraindications:
  – Allergy to colophony (resin from conifers) - rare
  – Ulcerative gingivitis and/or stomatitis
  – Pulp exposure or deep decay

*Recommendations for Using Fluoride to Prevent and Control Dental Caries in United States (CDC)*
https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5014a1.htm
Fluoride Varnish – Who Can Apply?

• Medical Office Setting
  – MD
  – Trained nurses and assistants
    • With MD/NP order *

• Community Setting**
  (School, health fair or government program)
  – Any trained person
    • With signed parent/guardian permission
    • Under a doctor’s (or dentist’s) prescription
    • Following doctor’s (or dentist’s) protocol

*CHDP Provider Information Notice No.:06-08 & **Policy Pick: Topical Fluoride Varnish and AB667
Fluoride Varnish –
Supplies Needed

- Gauze
- Gloves
- Varnish Packet
- Tray or napkin(s)
- Hand sanitizer
- Optional
  - Mouth Mirror
  - Toothbrush
- Post Procedure - FV Brochure
Fluoride Varnish – How to Apply?

1. Dry teeth with gauze
2. Apply to all surfaces
3. Apply to front teeth
4. Apply to bottom teeth
Fluoride Varnish Procedure

Prepare for treatment before positioning child
1. OPEN the packet of varnish
2. BEND the Brush
3. WRAP the gauze around finger

Next - position the child securing arms and legs
4. STIR varnish with applicator
5. DRY teeth lightly with gauze
Fluoride Varnish – Positioning
Fluoride Varnish Procedure - continued

6. Work in sections
7. Retract cheeks with gauzed finger
8. Begin with upper right section of teeth.
9. Repeat on left side
10. Continue this method on lower right and left sections

Brush all surfaces of teeth focusing on:
- Where gums and teeth meet
- Chewing surfaces of molars
- Upper front teeth – do not forget “tongue” side (lingual)
Fluoride Varnish Procedure –
Key Point: Focus on Critical Teeth Surfaces

Apply to:

- Chewing surfaces of molars, into fissures and between teeth
- Upper front teeth – do not forget “tongue” side
- Where gums and teeth meet
Fluoride Varnish –
Parent Information

• No water restrictions after application
• Avoid crunchy, chewy, and hot foods/drinks for the rest of the day
• Do not brush/floss until the next day
• Fluoride Varnish may leave a light color coating that will be brushed off the next day

Print copies of Fluoride Varnish – Helping Smiles Stay Strong brochure
Fluoride Varnish – Talking Points

• Fluoride Varnish does not take the place of:
  – A dental visit
  – Brushing with fluoride toothpaste twice a day
  – Limiting sweets or sugary snacks
  – Drinking fluoridated tap water

• In addition to fluoride varnish at medical offices, dentists can also provide fluoride varnish or other topical fluoride treatments twice a year.
Fluoride Varnish - Billing

Reimbursable 3 times (in a 12 month period) for children age 0 through 5

• Fee-for-Service Medi-Cal
  – Billing code: CPT 99188*
  – Reimbursement - $18 per application

• Managed Care Medi-Cal
  – Reimbursement varies
  – Contact individual plan

• FQHC/RHC/IHS
  – Not billable as a separate procedure

*Medi-Cal Rates (Codes 94799 thru 99600) (DHCS)
Fluoride Varnish – How to Order

Three Ways:

1. Directly:
   – Center for Oral Health 909-469-8300
     https://centerfororalhealth.org/store/

2. Choose from list:
   – AAP Ordering list

3. Internet search:
   – Use search term “fluoride varnish buy”
Fluoride Varnish – How to Implement in Your Practice

- Establish Health Records (EMR) for documentation
- Engage staff - information meetings
- Practicum training
- Identify champion(s)
- Identify workflow
- Train on documentation
- Publicize to patient parents
- Set start date
- Share progress
Fluoride Varnish – Establish a Protocol

• Identify:
  – ages to get FV
  – interval periods

• Establish standing order - Rx

• Assign duties to MA, or other trained staff

• Document in health record

• Give post procedure instructions

• Start slowly
Easy and Effective

• Can be delegated to nursing and medical assistant staff, which empowers them to be the front line against oral disease.
• Can be applied at any time after the oral assessment.
• Can prevent a cavity with a swipe of a fluoride varnish brush.
Fluoride Varnish
Online Trainings

Videos

American Academy of Pediatrics Television
http://www.youtube.com/watch?v=ZNOIGS1ggSg&feature=player

Smiles for Life University of Connecticut
http://www.youtube.com/watch?v=cV5OmL7C8K4&feature=player

Modules

Maryland’s Mouths Matter Module 4
http://www.mchoralhealth.org/fluvarnish/mod4_0.html

Smiles for Life Training: Course #6
https://www.smilesforlifeoralhealth.org/buildcontent.aspx?pagekey=66053&lastpagekey=64596&userkey=13873165&sessionkey=4170799&tut=584&customerkey=84&custsitegroupkey=0
Working Together

Together we can stop the epidemic of oral disease!

Medical Providers

Dental Providers

Parents/Caregivers

Individuals

Local CHDP Program Contact Information
http://www.dhcs.ca.gov/services/chdp/Pages/CountyOffices.aspx
Questions?
Fluoride Varnish - Practicum -

• Speaker Demonstration
• Participant Practice
Thank you!

To view resources for this training, visit the References page
(http://www.dhcs.ca.gov/services/chdp/Documents/CHDPDental/Slide19.pptx)

To access this training, visit CHDP Dental and other trainings
(www.dhcs.ca.gov/services/chdp/Pages/Training.aspx)

Visit the CHDP County Offices website for your local CHDP contact information
(www.dhcs.ca.gov/services/chdp/Pages/CountyOffices.aspx)

Photos and graphics in this training were used by permission or from public domain.
In this Issue:
- International Travel Planning for the Holidays
- Immunization Updates – Back-to-School
- Influenza – 2019-2020 Season Updates
- Botulism – A Health Emergency
- Rabies – Postexposure Prophylaxis

Disease Reporting
- List of Reportable Diseases
- Confidential Morbidity Reports
- List of Laboratory Reportable Diseases

Communicable Diseases
8am – 5pm, M-F
Phone: (925) 313-6740
Fax: (925) 313-6465

Sexually Transmitted Diseases
8am – 5pm, M-F
Phone: (925) 313-6750
Fax: (925) 313-6758

Public Health Laboratory
8am – 5pm, M-F
Phone: (925) 370-5775
Fax: (925) 370-5252

After Hours Public Health
5pm – 8am, M-F and 24hrs, Sat and Sun
Call County Sheriff’s Dispatch
Phone: (925) 646-2441
Ask for Health Officer On-Call

To Our Health Partners in the Community
Please visit https://cchealth.org/providers/ to subscribe to our electronic version of this newsletter and view local health alerts and advisories. Please contact us at CoCoCD@cchealth.org with suggested newsletter topics and comments. For urgent questions or to report a communicable disease, please call us at (925) 313-6740.

International Travel Planning
The Holidays are a popular time for extended international travel to visit friends and family. Measles, typhoid fever, and vector-borne diseases are some of the conditions we see in Contra Costa County residents returning from abroad. For more information, check the CDC Travelers’ Health webpage for country travel advisories and disease specific health recommendations: https://wwnc.cdc.gov/travel

Measles
Make sure your patients who are traveling internationally are protected from measles. There are measles outbreaks occurring in many areas of the world, including the US, Europe, Asia and Africa. The CDC recommends that all international travelers be protected against measles. Before traveling internationally,
- Infants (6-11 months): one doses of measles-mumps-rubella (MMR) vaccine.
- Children (1 year or older): 2 doses MMR vaccine. The doses can be given outside routine schedule and as close as 28 days apart.
- Adults: documentation of 2 doses of measles-containing vaccine or evidence of immunity.

For more information: https://www.cdc.gov/measles/hcp/index.html

Typhoid Fever
Typhoid fever is common worldwide except in industrialized regions such as the US, Canada, western Europe, Australia, and Japan. US travelers to typhoid-endemic regions should receive pre-travel vaccination at least 1-2 weeks before traveling. US travelers to typhoid-endemic regions should also be advised regarding safe food and water practices while abroad.

Other Routine Vaccinations
Travelers may also need routine (non-travel) vaccines or boosters before travel including: influenza, tetanus (Td or Tdap), varicella, pneumococcus, and polio.

Malaria
It is important to discuss malaria prophylaxis with ALL travelers who are going to areas with malaria transmission, regardless of previous travel or habitation in that area. All travelers going to malaria-endemic countries, which include parts of Africa, Latin America, the Caribbean, Asia, the Middle East, Eastern Europe, and the South Pacific are at risk for contracting the disease. Almost all the approximately 1,700 cases of malaria per year in the United States are imported cases of disease.

General Mosquito-Borne Disease Precautions
To decrease risk of all mosquito-borne diseases (e.g. chikungunya, dengue, yellow fever, zika, etc.) advise patients to prevent mosquito bites by using insect repellents, wearing long-sleeve shirts and pants, and sleeping under a mosquito bed net if sleeping outside or in a room that does not have screens or air conditioning.
Immunization Updates

School Entry Immunizations

Students entering childcare, preschool, transitional kindergarten and grades K-12 will need proof of vaccination for admission per California law.

Parents must show their child’s Immunization Record as proof of immunization.

For more information on requirements by age/grade level, visit: https://www.shotsforschool.org/

Required Immunizations for School Admissions: Guidance Changes as of July 1, 2019:

- NEW! Varicella (Chickenpox)
  2 doses are now required for 7th grade

Influenza 2019-2020 Season Updates

Routine annual influenza vaccination is recommended for all persons aged 6 months and above who do not have contraindications to vaccination. Optimally, vaccination should occur before the onset of influenza activity in the community. Health care providers should offer vaccination by the end of October, if possible. Vaccination should continue through the spring.

Influenza Vaccine Formulation for 2019-20:
- A/Brisbane/02/2018 (H1N1)pdm09-like virus*
- A/Kansas/14/2017 (H3N2)-like virus*
- B/Colorado/06/2017–like virus (Victoria lineage)
- B/Phuket/3073/2013-like virus (quadrivalent formulations only)
*new for this year

Vaccination Recommendations

Children Aged 6 Months Through 8 Years**: For optimum protection the Advisory Committee on Immunization Practices (ACIP) recommends that children aged 6 months through 8 years who have not previously received ≥2 doses of trivalent or quadrivalent influenza vaccine before July 1, 2019 (these doses do not need to be administered in consecutive seasons) receive 2 doses for the 2019-20 season. The interval between the 2 doses should be at least 4 weeks.

Pregnant Women**: Pregnant and postpartum women are at higher risk for severe illness and complications from influenza, particularly during the second and third trimesters. ACIP and the American College of Obstetricians and Gynecologists recommend that all women who are pregnant or who might be pregnant during the influenza season receive influenza vaccine. Any licensed, recommended, and age-appropriate preservative-free flu vaccine may be used. Intranasal flu vaccine (FluMist) should not be used during pregnancy. Influenza vaccine can be administered at any time during pregnancy.

** Per California law, pregnant women and children under 3 years of age may only receive preservative-free vaccine.

Older Adults: Because of the vulnerability of this population to severe influenza illness, hospitalization, and death, influenza vaccination among older adults is recommended. High dose and adjuvanted flu vaccine have better effectiveness in this population, however there is no formal preference for any vaccine product by the ACIP. For persons aged ≥65 years, any age-appropriate influenza formulation (standard-dose or high-dose, trivalent or quadrivalent, adjuvanted or not) or recombinant inactivated influenza vaccine are acceptable options. Vaccination should not be delayed if a specific product is not readily available.

For more information, see the recent report ‘Prevention and Control of Seasonal Influenza with Vaccines’ (CDC MMWR, August 23, 2019) https://www.cdc.gov/mmwr/volumes/68/rr/rr6803a1.htm?s_cid=rr6803a1_w

Prevention & Control Activities

Outbreak Detection and Reporting

Report to Public Health (per Title 17, California Code of Regulations (CCR) §2500 & 2505)
1. Laboratory-Confirmed influenza-related pediatric deaths (ages 0-17 years)
2. Acute Respiratory Outbreaks in both healthcare and congregate living settings, such as residential living facilities (retirement community, assisted living, board & care, skilled nursing facilities, rehabilitation centers, homeless and evacuation shelters, camps, jails, etc.)

An outbreak is defined as:
- One lab-confirmed influenza case in a healthcare or congregate living setting.
- 2 or more cases of new onset respiratory illness within 72 hours (3 days) in a healthcare or congregate living setting.
- Any influenza illness associated with animal exposure (pigs, poultry, and other animals that can be infected with variant influenza viruses).
Botulism

**Botulism is a neuroparalytic illness caused by Clostridium botulinum neurotoxins.** Early symptoms may include double/blurred vision, drooping eyelids, slurred speech, difficulty swallowing, dry mouth, and muscle weakness. Neurologic symptoms generally begin 12 to 36 hours after ingestion of toxin and can progress to a symmetric, descending flaccid paralysis that begins in the cranial nerves.

Untreated, botulism can progress to respiratory paralysis and death. If administered early in the course of illness, botulism antitoxin can stop the progression of, but cannot reverse, paralysis. Antitoxin is available exclusively from public health authorities.

**How to Obtain Antitoxin**

As soon as botulism is suspected, call the Public Health Communicable Disease (CD) to start the process of obtaining antitoxin. CD staff can be reached at 925-313-6740 or, after-hours (M-F 5pm to 8am and 24hrs Sat. & Sun.), call County Sheriff’s dispatch at 925-646-2441 and ask for the Health Officer on-call.

If infant botulism is suspected, contact the California Infant Botulism Program directly to obtain infant antitoxin (BabyBIG) at: [www.infantbotulism.org/physician/obtain.php](http://www.infantbotulism.org/physician/obtain.php)

Serum samples along with stool specimens should be collected prior to antitoxin administration for botulism testing, but do not wait for the results of testing before administering antitoxin. Patients should be given antitoxin as soon as it is available. Laboratory info: [www.cdph.ca.gov/Programs/CID/DCDC/Pages/TestOrderAdultBot.aspx](http://www.cdph.ca.gov/Programs/CID/DCDC/Pages/TestOrderAdultBot.aspx)

**Three Main Types of Botulism**

- **Foodborne botulism** – acquired by eating food contaminated with botulinum toxin. Common food sources include: home-canned, preserved or fermented foods. Commercial foods that are improperly prepared or stored can also be a source of toxin.
- **Wound botulism** – wounds can become infected with C. botulinum bacteria. Persons who inject drugs are at increased risk of becoming infected with wound botulism.
- **Infant botulism** – spores get into intestines where they grow and produce toxin and subsequent illness.

**Timely Public Health Investigation**

Although foodborne botulism remains a rare occurrence in California, each case represents a medical and public health emergency. The CD Programs conduct a thorough investigation of every botulism case to determine the source. If foodborne botulism is suspected, the CD Programs work with the Contra Costa Environmental Health Program to identify the food item and remove it from distribution as quickly as possible.

---

Rabies

**Timely Reporting to Animal Services & Administration of Postexposure Prophylaxis**

Rabies virus is transmitted when a rabid animal bites a human or another mammal and virus-laden saliva enters the wound, incubating in the muscle tissue before making its way through the nervous system to the brain. Although rabies is almost always fatal, rabies postexposure prophylaxis (PEP) is extremely effective at preventing disease. Rabies PEP consists of infusing rabies immunoglobulin directly around the wound and administering the rabies vaccine series.

In California, rabies can be found in certain wildlife species and has the potential to spread to pets, farm animals, and people. Bats are most commonly found to be infected with rabies, but rabies has also been detected in other wild animals such as skunks and foxes. Rabies is rarely identified in domestic animals such as dogs and cats due to routine vaccination, but unvaccinated domestic animals who have had contact with wildlife can become infected.

**Postexposure Prophylaxis (PEP): Urgency of RIG and Rabies Vaccine Administration**

Rabies PEP, administered after a possible exposure, is highly effective at preventing the progression to rabies disease. However, once an infected person develops symptoms of rabies there is no effective treatment and the infected person will likely die within a few days.

**Download a copy of this poster:** [https://cchealth.org/rabies/pdf/bites-from-wildlife.pdf](https://cchealth.org/rabies/pdf/bites-from-wildlife.pdf)

**Bite Report: Initiation of Animal Services Investigation & Quarantine of Implicated Animal**


---

**More resources at cchealth.org/providers/**

Contra Costa Public Health
Communicable Disease Programs
597 Center Ave. Suite 200-A
Martinez, CA 94553
Phone: (925) 313-6740
Fax: (925) 313-6465
EMAIL: CoCoCD@cchealth.org
New Revisions of USPSTF Recommendations

<table>
<thead>
<tr>
<th>Topic</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRCA risk assessment</td>
<td>The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations with an appropriate brief familial risk assessment tool. Women with a positive result on the risk assessment tool should receive genetic counseling and, if indicated after counseling, genetic testing.</td>
</tr>
<tr>
<td>(Asymptomatic) Bacteriuria screening: pregnant women</td>
<td>The USPSTF recommends screening for asymptomatic bacteriuria using urine culture in pregnant persons.</td>
</tr>
<tr>
<td>Breast cancer preventive medications</td>
<td>The USPSTF recommends that clinicians offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to women who are at increased risk for breast cancer and at low risk for adverse medication effects.</td>
</tr>
</tbody>
</table>

In 2005 and 2013, the USPSTF recommended that women whose family history is associated with an increased risk for potentially harmful mutations in the BRCA1/2 genes be referred for genetic counseling and evaluation for BRCA1/2 testing. It also recommended against routine referral for genetic counseling or routine BRCA1/2 mutation testing for women whose family history is not associated with an increased risk for potentially harmful mutations in the BRCA1/2 genes.\(^4\)\(^,\)\(^47\) This Recommendation Statement is consistent with the USPSTF’s previous recommendation.

Since 2013, the validity of genetic testing for BRCA1/2 mutations has been established and the potential benefits and harms of previously reviewed interventions, such as risk-reducing medications and surgery, have been studied for longer follow-up periods. In addition, there have been more studies of newer imaging techniques (breast MRI), surgical procedures (salpingo-oophorectomy rather than oophorectomy alone), and medications (aromatase inhibitors). The updated recommendation expands the population eligible for screening to include women with a previous breast, ovarian, tubal, or peritoneal cancer diagnosis who have completed treatment and are considered cancer free and more explicitly includes ancestry associated with BRCA1/2 mutations (ie, founder mutations) as a risk factor.
In this update, the USPSTF continues to recommend screening for asymptomatic bacteriuria in pregnant persons with urine culture and recommends against screening in nonpregnant adults. The USPSTF changed the grade for pregnant persons from an “A” to a “B” based on the reduced applicability of the previous evidence that included outdated antibiotic treatment regimens and newer evidence that shows a significantly lower risk of pyelonephritis than found in previous reviews. In addition, there are newer concerns about antibiotic use, such as antimicrobial resistance and adverse changes to the microbiome (not addressed in current studies), leading to an increase in the magnitude of potential harms. These factors led the USPSTF to reduce assessments of certainty and magnitude of benefit, resulting in the change of grade.

Since 1996, the USPSTF has maintained an “A” recommendation for 1-time screening for asymptomatic bacteriuria with urine culture in pregnant persons between 12 and 16 weeks of gestation. The original 1996 recommendation was reaffirmed in 2004 and again in 2008. In 1996, the USPSTF found that there was insufficient evidence to recommend for or against screening in older adult women or women with diabetes and, in a separate recommendation, that screening was not recommended in other asymptomatic adults or older adults who reside in an institution. In 2004, these recommendations were combined into a single recommendation against screening, which was subsequently reaffirmed in 2008.

This recommendations is consistent with the 2013 USPSTF recommendation. As before, the USPSTF recommends offering risk-reducing medications to women at increased risk for breast cancer and at low risk for adverse medication effects (B recommendation) and recommends against routine use of risk-reducing medications in women not at increased risk (D recommendation). The current recommendation now includes aromatase inhibitors among medications that can reduce risk of breast cancer.
Contra Costa Health Plan

<table>
<thead>
<tr>
<th>INSURANCE TYPE</th>
<th>Medicaid</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRODUCT TYPE</td>
<td>HMO</td>
</tr>
<tr>
<td>WEBSITE</td>
<td><a href="http://www.czhealth.org">http://www.czhealth.org</a></td>
</tr>
<tr>
<td>STATE(S) SERVED</td>
<td>California</td>
</tr>
<tr>
<td>MEMBERS ENROLLED</td>
<td>178547</td>
</tr>
<tr>
<td>OTHER NAMES</td>
<td>Medi-Cal</td>
</tr>
</tbody>
</table>

Star Results

<table>
<thead>
<tr>
<th>ACCREDITATION CATEGORIES</th>
<th>RESULTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Access and Service</td>
<td>★★★</td>
</tr>
<tr>
<td>Access to needed care, offer good customer service.</td>
<td></td>
</tr>
<tr>
<td>Qualified Providers</td>
<td>★★★</td>
</tr>
<tr>
<td>Ensuring doctors are licensed and patients are satisfied with their care.</td>
<td></td>
</tr>
<tr>
<td>Staying Healthy</td>
<td>★★★</td>
</tr>
<tr>
<td>Helping people maintain good health.</td>
<td></td>
</tr>
<tr>
<td>Getting Better</td>
<td>★★★</td>
</tr>
<tr>
<td>Activities that help people get well.</td>
<td></td>
</tr>
<tr>
<td>Living with Illness</td>
<td>★★★</td>
</tr>
<tr>
<td>Activities that help people live well while being sick.</td>
<td></td>
</tr>
</tbody>
</table>

Overall Health Plan Accreditation

This plan is NCQA Commendable

<table>
<thead>
<tr>
<th>INSURANCE TYPE</th>
<th>Medicaid</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRODUCT TYPE</td>
<td>HMO</td>
</tr>
<tr>
<td>ACCREDITATION STATUS</td>
<td>Commendable</td>
</tr>
<tr>
<td>EVALUATION PRODUCT</td>
<td>Renewal Survey</td>
</tr>
<tr>
<td>STATUS MODIFIER</td>
<td>None</td>
</tr>
<tr>
<td>EXPIRATION DATE</td>
<td>02/24/20</td>
</tr>
<tr>
<td>NEXT REVIEW DATE</td>
<td>12/03/19</td>
</tr>
<tr>
<td>SCORED ON</td>
<td>Standards, HEDIS, CAHPS</td>
</tr>
</tbody>
</table>
Each child and family is unique; therefore, these Recommendations for Preventive Pediatric Health Care are designed for the care of children who are receiving competent parenting, have no manifestations of any important health problems, and are growing and developing in a satisfactory fashion. Developmental, psychosocial, and chronic disease issues for children and adolescents may require frequent counseling and treatment visits separate from preventive care visits. Additional visits also may become necessary if circumstances suggest variations from normal.

These recommendations represent a consensus by the American Academy of Pediatrics (AAP) and Bright Futures. The AAP continues to emphasize the great importance of continuity of care in comprehensive health supervision and the need to avoid fragmentation of care. Refer to the specific guidance by age as listed in the Bright Futures Guidelines (Hagan JF, Shaw JS, Duncan PM, eds. Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents. 4th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2017).

The recommendations in this statement do not indicate an exclusive course of treatment or standard of medical care. Variations, taking into account individual circumstances, may be appropriate. Copyright © 2019 by the American Academy of Pediatrics, updated March 2019. No part of this statement may be reproduced in any form or by any means without prior written permission from the American Academy of Pediatrics except for one copy for personal use.

---

### Table: Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents

<table>
<thead>
<tr>
<th>AGE</th>
<th>PRIMARY VISIT</th>
<th>3-5 d</th>
<th>Pre-school</th>
<th>Elementary</th>
<th>Middle</th>
<th>High School</th>
<th>College</th>
<th>Adolescence</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 m</td>
<td>1. Neonatal Evaluation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 m</td>
<td>2. A prenatal visit is recommended for parents who are at high risk, for first-time parents, and for those who request a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 m</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 m</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 m</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 m</td>
<td>3. Vaccinations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 m</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 m</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15 m</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18 m</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24 m</td>
<td>5. Screen, per &quot;Expert Committee Recommendations Regarding the Prevention, Assessment, and Treatment of Child</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30 m</td>
<td>4. Newborns should have an evaluation within 3 to 5 days of birth and within 48 to 72 hours after discharge from the</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>36 m</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>48 m</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54 m</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60 m</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>66 m</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>72 m</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### MEASUREMENTS

1. If a child comes under care for the first time at any point on the schedule, or if any items are not accomplished at the | | | | | | | | |
2. A prenatal visit is recommended for parents who are at high risk, for first-time parents, and for those who request a | | | | | | | | |
3. Vaccinations should have an evaluation after birth, and breastfeeding should be encouraged (and instruction and support should be offered). |
4. Newborns should have an evaluation within 3 to 5 days of birth and within 48 to 72 hours after discharge from the hospital to include evaluation for feeding and jaundice. Breastfeeding newborns should receive formal breastfeeding evaluation, and their mothers should receive encouragement and instruction, as recommended in "Breastfeeding and the Use of Human Milk" (http://pediatrics.aappublications.org/content/129/3/e827.full). Newborns discharged less than 48 hours after delivery must be examined within 48 hours of discharge, per "Hospital Stay for Healthy Term Newborns" (http://pediatrics.aappublications.org/content/125/2/405.full).
5. Screening should occur per "Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents" (http://pediatrics.aappublications.org/content/140/5/986.full). Blood pressure measurement in infants and children with specific risk conditions should be performed at visits before age 3 years.
6. A visual acuity screen is recommended at ages 4 and 5 years, as well as in cooperative 3-year-olds. Instrument-based screening may be used to assess risk at ages 12 and 24 months, in addition to the well visits at 3 through 5 years of age. See "Visual System Assessment in Infants, Children, and Young Adults by Pediatricians" (http://pediatrics.aappublications.org/content/137/1/e20153596) and "Procedures for the Evaluation of the Visual System by Pediatricians" (http://pediatrics.aappublications.org/content/137/1/e20153597).
7. In a visual acuity screen is recommended at ages 6 through 15 years and 17 years, and once between 18 and 21 years. See "The Sensitivity of Adolescent Hearing Screens Significantly Improves by Adding High Frequencies" (http://www.jahonline.org/article/S1054-139X(16)00048-3/fulltext).
8. The use of chaperones during the physical examination of the pediatric patient" (http://pediatrics.aappublications.org/content/126/5/1032).
9. Procedure should occur per "Identification and Evaluation of Children With Autism Spectrum Disorders" (http://pediatrics.aappublications.org/content/137/1/338.full).
10. The assessment should be family centered and may include an assessment of child social-emotional health, caregiver depression, and social determinants of health. See "Promoting Optimal Development: Screening for Behavioral and Emotional Problems" (http://pediatrics.aappublications.org/content/117/5/e1466).
12. Screening should occur per "Incorporating Recognition and Management of Perinatal and Postpartum Depression Into Pediatric Practice" (http://pediatrics.aappublications.org/content/127/5/991.full).
13. At each visit, age-appropriate physical examination is essential, with infants totally undressed and older children undressed and suitably draped. See "Use of Chaperones During the Physical Examination of the Pediatric Patient" (http://pediatrics.aappublications.org/content/127/5/981.full).

---

### Key:
- **M**: to be performed
- **R**: risk assessment to be performed with appropriate action to follow, if positive
- **V**: range during which a service may be provided

---

### Additional Resources

- Bright Futures/American Academy of Pediatrics
- American Academy of Pediatrics

---

#### Acknowledgments

This statement should be family centered and may include an assessment of child social-emotional health, caregiver depression, and social determinants of health. See "Promoting Optimal Development: Screening for Behavioral and Emotional Problems" (http://pediatrics.aappublications.org/content/117/5/e1466).

---

**License:** This document is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. For more information, see http://creativecommons.org/licenses/by-nc-nd/4.0/. This license lets others distribute your material, but they must not make changes to it. The license does not cover images, diagrams, or other content owned by third parties. For more information, see http://creativecommons.org/learn/sampling.
19. Confirm initial screen was accomplished, verify results, and follow-up, as appropriate. The Recommended Uniform Screening Panel (https://www.cdc.gov/ncbddd/bts/index.html) as determined by the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children, and state newborn screening laws/regulations (http://genes-r-us.uthscsa.edu/home) establish the criteria for and coverage of newborn screening procedures and programs.

20. Verify results as soon as possible, and follow up, as appropriate.

21. Confirm initial screening was accomplished, verify results, and follow-up, as appropriate. See “Hyperbilirubinemia in the Newborn Infant ≥35 Weeks’ Gestation: An Update With Clarifications” (http://pediatrics.aappublications.org/content/124/1/1132).


23. Schedules, per the AAP Committee on Infectious Diseases, are available at http://redbook.solutions.aap.org/SS/Immunization_Schedules.aspx. Every visit should be an opportunity to update and complete a vaccination record.


25. For children at risk of lead exposure, see “Prevention of Childhood Lead Toxicity” (http://www.cdc.gov/nceh/lead/ACCLPP/Final_Document_030712.pdf). Footnote 25 has been updated to read as follows: “For children at risk of lead exposure, see ‘Prevention of Childhood Lead Toxicity’.”


27. Tuberculosis testing per recommendations of the AAP Committee on Infectious Diseases is available at http://pediatrics.aappublications.org/content/138/1/e20161493.


29. Adolescents should be screened for sexually transmitted infections (STIs) per recommendations in the current edition of the AAP Red Book: Report of the Committee on Infectious Diseases.

30. Adolescents should be screened for HIV according to the USPSTF recommendations (http://www.uspreventiveservicestaskforce.org/uspstf/uspsdnch.htm) once between the ages of 16 and 18, making every effort to perform a risk assessment of the adolescent. Those at increased risk of HIV infection, including those who are sexually active, participate in injection drug use, or are being tested for other STIs, should be tested for HIV and reassessed annually.


35. If primary water source is deficient in fluoride, consider oral fluoride supplementation.

Summary of Changes Made to the Bright Futures/AAP Recommendations for Preventive Pediatric Health Care (Periodicity Schedule)

This schedule reflects changes approved in December 2018 and published in March 2019. For updates and a list of previous changes made, visit www.aap.org/periodicityschedule.

CHANGES MADE IN DECEMBER 2018

BLOOD PRESSURE

- Footnote 6 has been updated to read as follows: “Screening should occur per ‘Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents’ (http://pediatrics.aappublications.org/content/140/3/e20171904). Blood pressure measurement in infants and children with specific risk conditions should be performed at visits before age 3 years.”

ANEMIA

- Footnote 24 has been updated to read as follows: “Perform risk assessment or screening, as appropriate, per recommendations in the current edition of the AAP Pediatric Nutrition: Policy of the American Academy of Pediatrics (Iron chapter).”

LEAD

- Footnote 25 has been updated to read as follows: “For children at risk of lead exposure, see ‘Prevention of Childhood Lead Toxicity’ (http://pediatrics.aappublications.org/content/134/3/626) and ‘Low Level Lead Exposure Harms Children: A Renewed Call for Primary Prevention’ (https://www.cdc.gov/nceh/lead/ACCLPP/Final_Document_030712.pdf).”